荃信生物-B(02509)11月6日斥资199.61万港元回购8.92万股
Qyuns TherapeuticsQyuns Therapeutics(HK:02509) 智通财经网·2025-11-06 14:13

Core Viewpoint - Company announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - Company will repurchase 89,200 shares at a total cost of HKD 1.9961 million [1] - The buyback is scheduled for November 6, 2025, suggesting a strategic timing for the repurchase [1]